Logo

People in the News: Iain Ross, Steven Paul, Mark Levin

Sep 04, 2014
Premium

Biotech firm Amarantus Bioscience has appointed Iain Ross to its board of directors.

Ross is currently chairman of Ark Therapeutics and Biomer Technology. He is also a non-executive director of expressed RNAi firm Benitec Biopharma, and previously served as chairman of Silence Therapeutics.

Voyager Therapeutics has named Steven Paul, its interim president of research and development, as its new CEO.

Paul replaces Third Rock Venture partner Mark Levin, who served as the startup's interim CEO following the venture capital company's investment in Voyager earlier this year. Levin has now become Voyager's chairman.

Filed under

Gene Editing, Gene Silencing, & CRISPR
RNAi
Benitec
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.